Interaction between DNA/histone methyltransferases and their inhibitors

Current Medicinal Chemistry

Volumn 22, Issue 3, 2015, Pages 360-372

  Hu, J ^a   Chen, S ^a   Kong, X ^a   Zhu, K ^a   Cheng, S ^a   Zheng, M ^a   Jiang, H ^a   Luo, C ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

DNA methyltransferase; Drug discovery; Epigenetic therapy; Histone methyltransferase; Inhibitor

Indexed keywords

A 9; AMI 1; AMITROLE; AURINTRICARBOXYLIC ACID; AZ 505; AZACITIDINE; CBC 12; CHAETOCIN; CMPD 1; CP 4200; DECITABINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; EPZ 05687; GSK 126; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; N PHTHALOYLTRYPTOPHAN; NPEOC DAC; NSC 14778; NUCLEOTIDE DERIVATIVE; PROCAINAMIDE; RG 108 1; RM 65; SGI 1027; SID 49645275; SINEFUNGIN; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; PROTEIN BINDING;

ARTICLE; BIOLOGICAL FUNCTIONS; COMPUTER AIDED DESIGN; CRYSTALLOGRAPHY; DNA METHYLATION; DNA STRUCTURE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME STRUCTURE; GENE EXPRESSION; GENOME; HISTONE METHYLATION; HUMAN; NONHUMAN; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; PROTEIN BINDING;

EID: 84928687935     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141106114538     Document Type: Article

References (96)

1. Berger, S. L.; Kouzarides, T.; Shiekhattar, R.; Shilatifard, A. An operational definition of epigenetics. Genes Dev., 2009, 23(7), 781-783.
2. Foley, D. L.; Craig, J. M.; Morley, R.; Olsson, C. J.; Dwyer, T.; Smith, K.; Saffery, R. Prospects for epigenetic epidemiology. Am. J. Epidemiol., 2009, 169(4), 389-400.
3. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov., 2012, 11(5), 384-400.
4. Feinberg, A. P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 1983, 301(5895), 89-92.
5. Schreiber, S. L.; Bernstein, B. E. Signaling network model of chromatin. Cell, 2002, 111(6), 771-778.
6. Hatada, I. The Epigenomics of Cancer, 2010.
7. Zhang, R.; Lu, J.; Kong, X.; Jin, L.; Luo, C. Targeting epigenetics in nervous system disease. CNS Neurol. Disord.-Drug Targets, 2013, 12(1), 126-141.
8. Dammann, R.; Li, C.; Yoon, J. H.; Chin, P. L.; Bates, S.; Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genet., 2000, 25(3), 315-319.
9. Zheng, Y. G.; Wu, J.; Chen, Z.; Goodman, M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med. Res. Rev., 2008, 28(5), 645-687.
10. Renthal, W.; Nestler, E. J. Epigenetic mechanisms in drug addiction. Trends Mol. Med., 2008, 14(8), 341-350.
11. Jenuwein, T.; Allis, C. D. Translating the histone code. Science, 2001, 293(5532), 1074-1080.
12. Margueron, R.; Trojer, P.; Reinberg, D. The key to development: interpreting the histone code? Curr. Opin. Genet. Dev., 2005, 15(2), 163-176.
13. Wang, G. G.; Allis, C. D.; Chi, P. Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol. Med., 2007, 13(9), 363-372.
14. Zheng, M.; Liu, X.; Xu, Y.; Li, H.; Luo, C.; Jiang, H. Computational methods for drug design and discovery: focus on China. Trends Pharmacol. Sci., 2013, 34(10), 549-559.
15. Medina-Franco, J. L.; Lopez-Vallejo, F.; Kuck, D.; Lyko, F. Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol. Divers., 2011, 15(2), 293-304.
16. Medina-Franco, J. L.; Yoo, J. Molecular modeling and virtual screening of DNA methyltransferase inhibitors. Curr. Pharm. Des., 2013, 19(12), 2138-2147.
17. Siedlecki, P.; Boy, R. G.; Musch, T.; Brueckner, B.; Suhai, S.; Lyko, F.; Zielenkiewicz, P. Discovery of two novel, smallmolecule inhibitors of DNA methylation. J. Med. Chem., 2006, 49(2), 678-683.
18. Kuck, D.; Singh, N.; Lyko, F.; Medina-Franco, J. L. Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem., 2010, 18(2), 822-829.
19. Schermelleh, L.; Spada, F.; Easwaran, H. P.; Zolghadr, K.; Margot, J. B.; Cardoso, M. C.; Leonhardt, H. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat. Methods, 2005, 2(10), 751-756.
20. Schaefer, M.; Lyko, F. Solving the Dnmt2 enigma. Chromosoma, 2010, 119(1), 35-40.
21. Cheng, X.; Blumenthal, R. M. Mammalian DNA methyltransferases: a structural perspective. Structure, 2008, 16(3), 341-350.
22. Song, J.; Rechkoblit, O.; Bestor, T. H.; Patel, D. J. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science, 2011, 331(6020), 1036-1040.
23. Yoo, J.; Medina-Franco, J. L. Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase. J. Comput.-Aided Mol. Des., 2011, 25(6), 555-567.
24. Siedlecki, P.; Boy, R. G.; Comagic, S.; Schirrmacher, R.; Wiessler, M.; Zielenkiewicz, P.; Suhai, S.; Lyko, F. Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochem. Biophys. Res. Commun., 2003, 306(2), 558-563.
25. Brueckner, B.; Boy, R. G.; Siedlecki, P.; Musch, T.; Kliem, H. C.; Zielenkiewicz, P.; Suhai, S.; Wiessler, M.; Lyko, F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res., 2005, 65(14), 6305-6311.
26. Yoo, J.; Medina-Franco, J. L. Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: insights from enzymatic and molecular modeling studies. J. Mol. Model., 2012, 18(4), 1583-1589.
27. Castellano, S.; Kuck, D.; Viviano, M.; Yoo, J.; Lopez-Vallejo, F.; Conti, P.; Tamborini, L.; Pinto, A.; Medina-Franco, J. L.; Sbardella, G. Synthesis and biochemical evaluation of delta (2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors. J. Med. Chem., 2011, 54(21), 7663-7677.
28. Lyko, F.; Brown, R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. JNCI-J. Natl. Cancer Inst., 2005, 97(20), 1498-1506.
29. Schrump, D. S.; Fischette, M. R.; Nguyen, D. M.; Zhao, M.; Li, X.; Kunst, T. F.; Hancox, A.; Hong, J. A.; Chen, G. A.; Pishchik, V.; Figg, W. D.; Murgo, A. J.; Steinberg, S. M. Phase I study of decitabinemediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res., 2006, 12(19), 5777-5785.
30. Yoo, J.; Medina-Franco, J. L. Inhibitors of DNA methyltransferases: insights from computational studies. Curr. Med. Chem., 2012, 19(21), 3475-3487.
31. Byun, H. M.; Choi, S. H.; Laird, P. W.; Trinh, B.; Siddiqui, M. A.; Marquez, V. E.; Yang, A. S. 2'-Deoxy-N4-[2-(4-nitrophenyl) ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett., 2008, 266(2), 238-248.
32. Stresemann, C.; Lyko, F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer, 2008, 123(1), 8-13.
33. Moyers, S. B.; Kumar, N. B. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr. Rev., 2004, 62(5), 204-211.
34. Segura-Pacheco, B.; Trejo-Becerril, C.; Perez-Cardenas, E.; Taja-Chayeb, L.; Mariscal, I.; Chavez, A.; Acuna, C.; Salazar, A. M.; Lizano, M.; Duenas-Gonzalez, A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res., 2003, 9(5), 1596-1603.
35. Pina, I. C.; Gautschi, J. T.; Wang, G. Y. S.; Sanders, M. L.; Schmitz, F. J.; France, D.; Cornell-Kennon, S.; Sambucetti, L. C.; Remiszewski, S. W.; Perez, L. B.; Bair, K. W.; Crews, P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem., 2003, 68(10), 3866-3873.
36. Schnekenburger, M.; Dicato, M.; Diederich, M. Epigenetic modulators from "The Big Blue": A treasure to fight against cancer. Cancer Lett., 2014, 351(2), 182-197.
37. Suzuki, T.; Tanaka, R.; Hamada, S.; Nakagawa, H.; Miyata, N. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 1124-1127.
38. Asgatay, S.; Champion, C.; Marloie, G.; Drujon, T.; Senamaud-Beaufort, C.; Ceccaldi, A.; Erdmann, A.; Rajavelu, A.; Schambel, P.; Jeltsch, A.; Lequin, O.; Karoyan, P.; Arimondo, P. B.; Guianvarc'h, D. Synthesis and evaluation of analogues of N-phthaloyl-ltryptophan (RG108) as inhibitors of DNA methyltransferase 1. J. Med. Chem., 2014, 57(2), 421-434.
39. Datta, J.; Ghoshal, K.; Denny, W. A.; Gamage, S. A.; Brooke, D. G.; Phiasivongsa, P.; Redkar, S.; Jacob, S. T. A new class of quinolinebased DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res., 2009, 69(10), 4277-4285.
40. Yoo, J.; Choi, S.; Medina-Franco, J. L. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One, 2013, 8(4), e62152.
41. Milani, M.; Mastrangelo, E.; Bollati, M.; Selisko, B.; Decroly, E.; Bouvet, M.; Canard, B.; Bolognesi, M. Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition. Antiviral Res., 2009, 83(1), 28-34.
42. Bouvet, M.; Debarnot, C.; Imbert, I.; Selisko, B.; Snijder, E. J.; Canard, B.; Decroly, E. In vitro reconstitution of SARScoronavirus mRNA cap methylation. PLoS Pathog., 2010, 6 (4).
43. Medina-Franco, J. L.; Yoo, J. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: insights to unveil inhibitors in chemical databases. Mol. Divers., 2013, 17(2), 337-344.
44. Medina-Franco, J. L.; Caulfield, T. Advances in the computational development of DNA methyltransferase inhibitors. Drug Discov. Today, 2011, 16(9-10), 418-425.
45. Fischle, W.; Wang, Y. M.; Allis, C. D. Histone and chromatin crosstalk. Curr. Opin. Cell Biol., 2003, 15(2), 172-183.
46. Li, K. K.; Luo, C.; Wang, D.; Jiang, H.; Zheng, Y. G. Chemical and biochemical approaches in the study of histone methylation and demethylation. Med. Res. Rev., 2012, 32(4), 815-867.
47. Cao, R.; Wang, L. J.; Wang, H. B.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Jones, R. S.; Zhang, Y. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science, 2002, 298(5595), 1039-1043.
48. Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell, 2009, 33(1), 1-13.
49. Zhang, R.; Li, X.; Liang, Z.; Zhu, K.; Lu, J.; Kong, X.; Ouyang, S.; Li, L.; Zheng, Y. G.; Luo, C. Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1. PLoS One, 2013, 8 (8).
50. Bedford, M. T.; Richard, S. Arginine methylation: an emerging regulator of protein function. Mol. Cell, 2005, 18(3), 263-272.
51. Couture, J. F.; Collazo, E.; Brunzelle, J. S.; Trievel, R. C. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev., 2005, 19(12), 1455-1465.
52. Qian, C.; Zhou, M. M. SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell. Mol. Life Sci., 2006, 63(23), 2755-2763.
53. Zhang, X.; Zhou, L.; Cheng, X. D. Crystal structure of the conserved core of protein arginine methyltransferase PRMT3. Embo J., 2000, 19(14), 3509-3519.
54. Zhang, X.; Cheng, X. D. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure, 2003, 11(5), 509-520.
55. Yao, Y.; Chen, P. H.; Diao, J. S.; Cheng, G.; Deng, L. S.; Anglin, J. L.; Prasad, B. V. V.; Song, Y. C. Selective inhibitors of histone methyltransferase dot1l: design, synthesis, and crystallographic studies. J. Am. Chem. Soc., 2011, 133(42), 16746-16749.
56. 3 lysine-79 methyltransferase DOT1L. J. Med. Chem., 2013, 56(22), 8972-8983.
57. Subramanian, K.; Jia, D.; Kapoor-Vazirani, P.; Powell, D. R.; Collins, R. E.; Sharma, D.; Peng, J. M.; Cheng, X. D.; Vertino, P. M. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol. Cell, 2008, 30(3), 336-347.
58. Dowden, J.; Hong, W.; Parry, R. V.; Pike, R. A.; Ward, S. G. Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg. Med. Chem. Lett., 2010, 20(7), 2103-2105.
59. Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU (VAR) 3-9. Nat. Chem. Biol., 2005, 1(3), 143-145.
60. Kim, J.; Movassaghi, M. General approach to epipolythiodiketopiperazine alkaloids: total synthesis of (+)-chaetocins A and C and (+)-12, 12'-dideoxychetracin A. J. Am. Chem. Soc., 2010, 132(41), 14376-14378.
61. Iwasa, E.; Hamashima, Y.; Fujishiro, S.; Hashizume, D.; Sodeoka, M. Total syntheses of chaetocin and ent-chaetocin. Tetrahedron, 2011, 67(35), 6587-6599.
62. Sodeoka, M.; Dodo, K.; Teng, Y.; Iuchi, K.; Hamashima, Y.; Iwasa, E.; Fujishiro, S. Synthesis and biological activities of chaetocin and its derivatives. Pure Appl. Chem., 2012, 84(6), 1369-1378.
63. Takahashi, M.; Takemoto, Y.; Shimazu, T.; Kawasaki, H.; Tachibana, M.; Shinkai, Y.; Takagi, M.; Shin-ya, K.; Igarashi, Y.; Ito, A.; Yoshida, M. Inhibition of histone H3K9 methyltransferases by gliotoxin and related epipolythiodioxopiperazines. J. Antibiot., 2012, 65(5), 263-265.
64. De Lorbe, J. E.; Horne, D.; Jove, R.; Mennen, S. M.; Nam, S.; Zhang, F.-L.; Overman, L. E. General approach for preparing epidithiodioxopiperazines from trioxopiperazine precursors: enantioselective total syntheses of (+)- and (-)-gliocladine C, (+)-leptosin D, (+)-T988C, (+)-bionectin A, and (+)-gliocladin A. J. Am. Chem. Soc., 2013, 135(10), 4117-4128.
65. Kubicek, S.; O'Sullivan, R. J.; August, E. M.; Hickey, E. R.; Zhan, Q.; Teodoro, M. L.; Rea, S.; Mechtler, K.; Kowalski, J. A.; Homon, C. A.; Kelly, T. A.; Jenuwein, T. Reversal of H3K9me2 by a smallmolecule inhibitor for the G9a histone methyltransferase. Mol. Cell, 2007, 25(3), 473-481.
66. Chang, Y.; Zhang, X.; Horton, J. R.; Upadhyay, A. K.; Spannhoff, A.; Liu, J.; Snyder, J. P.; Bedford, M. T.; Cheng, X. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol., 2009, 16(3), 312-317.
67. Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A. M.; Wasney, G. A.; Dong, A.; Barsyte, D.; Kozieradzki, I.; Senisterra, G.; Chau, I.; Siarheyeva, A.; Kireev, D. B.; Jadhav, A.; Herold, J. M.; Frye, S. V.; Arrowsmith, C. H.; Brown, P. J.; Simeonov, A.; Vedadi, M.; Jin, J. Discovery of a 2, 4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem., 2009, 52(24), 7950-7953.
68. Chang, Y.; Ganesh, T.; Horton, J. R.; Spannhoff, A.; Liu, J.; Sun, A.; Zhang, X.; Bedford, M. T.; Shinkai, Y.; Snyder, J. P.; Cheng, X. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol., 2010, 400(1), 1-7.
69. Cheng, D.; Valente, S.; Castellano, S.; Sbardella, G.; Di Santo, R.; Costi, R.; Bedford, M. T.; Mai, A. Novel 3, 5-bis (bromohydroxybenzylidene) piperidin-4-ones as coactivatorassociated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity. J. Med. Chem., 2011, 54(13), 4928-4932.
70. Vedadi, M.; Barsyte-Lovejoy, D.; Liu, F.; Rival-Gervier, S.; Allali-Hassani, A.; Labrie, V.; Wigle, T. J.; Dimaggio, P. A.; Wasney, G. A.; Siarheyeva, A.; Dong, A.; Tempel, W.; Wang, S. C.; Chen, X.; Chau, I.; Mangano, T. J.; Huang, X. P.; Simpson, C. D.; Pattenden, S. G.; Norris, J. L.; Kireev, D. B.; Tripathy, A.; Edwards, A.; Roth, B. L.; Janzen, W. P.; Garcia, B. A.; Petronis, A.; Ellis, J.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Jin, J. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol., 2011, 7(8), 566-574.
71. Yuan, Y.; Wang, Q.; Paulk, J.; Kubicek, S.; Kemp, M. M.; Adams, D. J.; Shamji, A. F.; Wagner, B. K.; Schreiber, S. L. A smallmolecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem. Biol., 2012, 7(7), 1152-1157.
72. Liu, F.; Li, F.; Ma, A.; Dobrovetsky, E.; Dong, A.; Gao, C.; Korboukh, I.; Liu, J.; Smil, D.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Schapira, M.; Vedadi, M.; Jin, J. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J. Med. Chem., 2013, 56(5), 2110-2124.
73. Lin, Y.; Fan, H.; Frederiksen, M.; Zhao, K.; Jiang, L.; Wang, Z.; Zhou, S.; Guo, W.; Gao, J.; Li, S.; Harrington, E.; Meier, P.; Scheufler, C.; Xu, Y. C.; Atadja, P.; Lu, C.; Li, E.; Gu, X. J. Detect ing S-adenosyl-L-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescencebased binding assay. Anal. Biochem., 2012, 423(1), 171-177.
74. Ferguson, A. D.; Larsen, N. A.; Howard, T.; Pollard, H.; Green, I.; Grande, C.; Cheung, T.; Garcia-Arenas, R.; Cowen, S.; Wu, J.; Godin, R.; Chen, H.; Keen, N. Structural basis of substrate methylation and inhibition of SMYD2. Structure, 2011, 19(9), 1262-1273.
75. Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.; Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.; Song, J.; Scott, M. P.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth, R.; Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock, R. M.; Kuntz, K. W. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol., 2012, 8(11), 890-896.
76. Knutson, S. K.; Kawano, S.; Minoshima, Y.; Warholic, N. M.; Huang, K. C.; Xiao, Y.; Kadowaki, T.; Uesugi, M.; Kuznetsov, G.; Kumar, N.; Wigle, T. J.; Klaus, C. R.; Allain, C. J.; Raimondi, A.; Waters, N. J.; Smith, J. J.; Porter-Scott, M.; Chesworth, R.; Moyer, M. P.; Copeland, R. A.; Richon, V. M.; Uenaka, T.; Pollock, R. M.; Kuntz, K. W.; Yokoi, A.; Keilhack, H. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther., 2014, 13(4), 842-854.
77. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra, A. 3rd; Diaz, E.; La France, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492(7427), 108-112.
78. Qi, W.; Chan, H. M.; Teng, L.; Li, L.; Chuai, S. N.; Zhang, R. P.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J. H.; Yan, X. X.; Fang, J. L.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z. J.; Li, G. B.; Yang, T.; Zhao, K. H.; Liu, X. H.; Yu, Z. T.; Lu, C. X.; Atadja, P.; Li, E. Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(52), 21360-21365.
79. Verma, S. K.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J. L.; Grant, S. W.; Brackley, J. A.; Graves, A. P.; Scherzer, D. A.; Shu, A.; Thompson, C.; Ott, H. M.; Aller, G. S.; Machutta, C. A.; Diaz, E.; Jiang, Y.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P. J.; Creasy, C. L.; Miller, W. H. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett., 2012, 3(12), 1091-1096.
80. Konze, K. D.; Ma, A.; Li, F.; Barsyte-Lovejoy, D.; Parton, T.; Macnevin, C. J.; Liu, F.; Gao, C.; Huang, X. P.; Kuznetsova, E.; Rougie, M.; Jiang, A.; Pattenden, S. G.; Norris, J. L.; James, L. I.; Roth, B. L.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Hahn, K. M.; Wang, G. G.; Vedadi, M.; Jin, J. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol., 2013, 8(6), 1324-1334.
81. Sato, T.; Kaneda, A.; Tsuji, S.; Isagawa, T.; Yamamoto, S.; Fujita, T.; Yamanaka, R.; Tanaka, Y.; Nukiwa, T.; Marquez, V. E.; Ishikawa, Y.; Ichinose, M.; Aburatani, H. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep, 2013, 3, 1911.
82. Van Aller, G. S.; Pappalardi, M. B.; Ott, H. M.; Diaz, E.; Brandt, M.; Schwartz, B. J.; Miller, W. H.; Dhanak, D.; McCabe, M. T.; Verma, S. K.; Creasy, C. L.; Tummino, P. J.; Kruger, R. G. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem. Biol., 2014, 9(3), 622-629.
83. Cheng, D. H.; Yadav, N.; King, R. W.; Swanson, M. S.; Weinstein, E. J.; Bedford, M. T. Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem., 2004, 279(23), 23892-23899.
84. Ragno, R.; Simeoni, S.; Castellano, S.; Vicidomini, C.; Mai, A.; Caroli, A.; Tramontano, A.; Bonaccini, C.; Trojer, P.; Bauer, I.; Brosch, G.; Sbardella, G. Small molecule inhibitors of histone arginine methyltransferases: Homology modeling, molecular docking, binding mode analysis, and biological evaluations. J. Med. Chem., 2007, 50(6), 1241-1253.
85. Fontan, N.; Garcia-Dominguez, P.; Alvarez, R.; de Lera, A. R. Novel symmetrical ureas as modulators of protein arginine methyl transferases. Bioorg. Med. Chem., 2013, 21(7), 2056-2067.
86. Spannhoff, A.; Sippl, W.; Jung, M. Cancer treatment of the future: Inhibitors of histone methyltransferases. Int. J. Biochem. Cell Biol., 2009, 41(1), 4-11.
87. Spannhoff, A.; Machmur, R.; Heinke, R.; Trojer, P.; Bauer, I.; Brosch, G.; Schuele, R.; Hanefeld, W.; Sippl, W.; Jung, M. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg. Med. Chem. Lett., 2007, 17(15), 4150-4153.
88. Castellano, S.; Spannhoff, A.; Milite, C.; Dal Piaz, F.; Cheng, D.; Tosco, A.; Viviano, M.; Yamani, A.; Cianciulli, A.; Sala, M.; Cura, V.; Cavarelli, J.; Novellino, E.; Mai, A.; Bedford, M. T.; Sbardella, G. Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1. J. Med. Chem., 2012, 55(22), 9875-9890.
89. Purandare, A. V.; Chen, Z.; Huynh, T.; Pang, S.; Geng, J.; Vaccaro, W.; Poss, M. A.; Oconnell, J.; Nowak, K.; Jayaraman, L. Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2008, 18(15), 4438-4441.
90. Allan, M.; Manku, S.; Therrien, E.; Nguyen, N.; Styhler, S.; Robert, M. F.; Goulet, A. C.; Petschner, A. J.; Rahil, G.; MacLeod, A. R.; Deziel, R.; Besterman, J. M.; Nguyen, H.; Wahhab, A. N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2009, 19(4), 1218-1223.
91. Huynh, T.; Chen, Z.; Pang, S. H.; Geng, J. P.; Bandiera, T.; Bindi, S.; Vianello, P.; Roletto, F.; Thieffine, S.; Galvani, A.; Vaccaro, W.; Poss, M. A.; Trainor, G. L.; Lorenzi, M. V.; Gottardis, M.; Jayaraman, L.; Purandare, A. V. Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2009, 19(11), 2924-2927.
92. Therrien, E.; Larouche, G.; Manku, S.; Allan, M.; Nguyen, N.; Styhler, S.; Robert, M. F.; Goulet, A. C.; Besterman, J. M.; Nguyen, H.; Wahhab, A. 1, 2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett., 2009, 19(23), 6725-6732.
93. Sack, J. S.; Thieffine, S.; Bandiera, T.; Fasolini, M.; Duke, G. J.; Jayaraman, L.; Kish, K. F.; Klei, H. E.; Purandare, A. V.; Rosettani, P.; Troiani, S.; Xie, D. L.; Bertrand, J. A. Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem. J., 2011, 436, 331-339.
94. Wang, J.; Chen, L.; Sinha, S. H.; Liang, Z.; Chai, H.; Muniyan, S.; Chou, Y.-W.; Yang, C.; Yan, L.; Feng, Y.; Li, K. K.; Lin, M.-F.; Jiang, H.; Zheng, Y. G.; Luo, C. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. J. Med. Chem., 2012, 55(18), 7978-7987.
95. Antonysamy, S.; Condon, B.; Druzina, Z.; Bonanno, J. B.; Gheyi, T.; Zhang, F.; MacEwan, I.; Zhang, A.; Ashok, S.; Rodgers, L.; Russell, M.; Luz, J. G. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by x-ray crystallographic analysis of the EZH2-SET domain. PLoS One, 2013, 8 (12).
96. Zagni, C.; Chiacchio, U.; Rescifina, A. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr. Med. Chem., 2013, 20(2), 167-185.